/HOLX
Hologic, Inc.
HOLX • NASDAQHOLX • NASDAQ • Healthcare
$75.21-0.27%-0.20
$75.21-0.27%(-0.20)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
51Neutral
Risk
91Low Risk
Momentum
60Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
61.0%▲5.7pp
Revenue after COGS
Operating
17.4%▼4.5pp
After operating expenses
Net
13.8%▼5.8pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
27.0
Price vs earnings
EV/EBITDA
15.6
Enterprise value
FCF Yield
6.0%
Cash generation
Earnings Yield
3.7%
Inverse of P/E
Capital Efficiency
8
GoAI Quality ScoreFair
ROEReturn on Equity
11.2%Fair
ROAReturn on Assets
6.3%Strong
ROICReturn on Invested Capital
7.3%Fair
Financial Health
Current RatioHealthy
3.75
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
0.65x
Debt repayment capacity (<3x)
Income QualityStrong
1.87
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.10B | $4.03B | $4.03B | $4.86B | $5.63B |
| Gross Profit | $2.50B | $2.23B | $2.07B | $3.00B | $3.80B |
| Gross Margin | 61.0% | 55.3% | 51.4% | 61.6% | 67.4% |
| Operating Income | $714.30M | $882.60M | $668.40M | $1.64B | $2.48B |
| Net Income | $565.70M | $789.50M | $456.00M | $1.30B | $1.87B |
| Net Margin | 13.8% | 19.6% | 11.3% | 26.8% | 33.2% |
| EPS | $2.50 | $3.35 | $1.85 | $5.18 | $7.28 |
Average Price Target
$77.80▲ 3.4% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Hologic, Inc., the average price target is $77.80, with a high forecast of $79.00 and a low forecast of $76.00. The average price target represents a 3.4% increase from the current price of $75.21.
Highest
$79.00
Average
$77.80
Lowest
$76.00
Rating Distribution
Strong Buy
0
0%
Buy
18
43%
Hold
23
55%
Sell
1
2%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Argus Research▼ Downgrade
Buy→Hold
2026-01-12Evercore ISI Group▼ Downgrade
Outperform→In Line
2026-01-05Morgan Stanley● Maintain
Equal Weight
2025-11-11Mizuho▼ Downgrade
Outperform→Neutral
2025-10-23Raymond James▼ Downgrade
Outperform→Market Perform
2025-10-22JP Morgan▼ Downgrade
Overweight→Neutral
2025-10-22Stephens & Co.▼ Downgrade
Overweight→Equal Weight
2025-10-22Needham● Maintain
Hold
2025-10-21BTIG● Maintain
Neutral
2025-10-21Leerink Partners● Maintain
Market Perform
2025-10-21Earnings History & Surprises
BEAT RATE
89%
Last 18 quarters
AVG SURPRISE
+16.0%
EPS vs Estimate
BEATS / MISSES
16/1
1 met exactly
LATEST EPS
$1.04
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
-5.5%
$1.04 vs $1.10
Q4 '25
+2.7%
$1.13 vs $1.10
Q3 '25
+2.9%
$1.08 vs $1.05
Q2 '25
+1.0%
$1.03 vs $1.02
Q1 '25
+1.0%
$1.03 vs $1.02
Q4 '24
$1.01 vs $1.01
Q3 '24
+3.9%
$1.06 vs $1.02
Q2 '24
+5.3%
$1.03 vs $0.98
Q1 '24
+3.2%
$0.98 vs $0.95
Q4 '23
+4.7%
$0.89 vs $0.85
Q3 '23
+5.7%
$0.93 vs $0.88
Q2 '23
+20.5%
$1.06 vs $0.88
No investor questions available.
Latest News
No news available